The introduction of targeted cancer drugs fulfilled the promise of personalized (precision) medicine, offering great benefit to some patients, great expense to others. Martell was organized to launch the next paradigm—how best to manage precision treatments. This can be accomplished with inexpensive blood tests that quickly document drug efficacy, remission and recurrence. We consider our mission de-escalation: less medication, less cost, a better quality of life.
Metastatic breast cancer is now considered a chronic condition with effective treatments that in many ways allow women to lead a normal or near normal life. Yet, many women live with the fear that their cancer may no longer be responding to medication or the disease has flared in advance of overt clinical symptoms. We believe that a simple blood test can effectively monitor medication and help detect recurrences of HER2 tumors. Plus, monitoring helps to reduce anxiety. Therein lies the value of HERTEST for women with metastatic HER2 tumors—the possibility of real-time, actionable information and additional peace of mind.
The PD-1/PD-L1 axis is an important mechanism often regulating tumor growth. Recognition has led to the introduction of new drugs called checkpoint inhibitors. Sometimes spectacular, always expensive, treatment could be better managed with a monitoring blood test. Martell is introducing CHECKMARK with the hope it will fulfill that need.
Business model: reference laboratory
Location: Roseville, MN